Skip to main content
2024 Guide to Patient Support Services

ADC Therapeutics

2024 PSS Guide

ADC Therapeutics Advancing Patient Support

This email address is being protected from spambots. You need JavaScript enabled to view it.

ADC Therapeutics offers the Advancing Patient Support program to assist patients and their healthcare providers access to Zynlonta (Table).

Advancing Patient Support

The Advancing Patient Support program can serve as a single point of contact to help patients get started and stay on Zynlonta. Case managers can assist with coverage support such as benefits investigation, financial support through the Copay Assistance Program and the Patient Assistance Program, and nursing support to answer questions about treatment with Zynlonta.

Copay Assistance Program

Please see https://www.advancingpatientsupport.com/copayterms-conditions/ for eligibility criteria.

Patient Assistance Program

Advancing Patient Support’s Patient Assistance Program offers patients who are uninsured or underinsured Zynlonta for free if they meet certain criteria. To determine eligibility to enroll in the Patient Assistance Program, ADC Therapeutics and its representatives will assess the patient’s income and verify financial information with W-2 and tax return documentation.

Enroll your patient in the Advancing Patient Support program by either completing the form online or by downloading the form and submitting via fax at 855-915-3005 or e-mailing to This email address is being protected from spambots. You need JavaScript enabled to view it..

TABLE ADC Therapeutics Oncology Drug

Drug
Indication
Patient support program

Drug
Zynlonta (loncastuximab tesirine-lpyl) for injection
Indication
Treatment of adult patients with relapsed or refractory large B-cell lymphoma after 2 or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising from low-grade lymphoma, and high-grade B-cell lymphoma
Patient support program
Advancing Patient Support Program This email address is being protected from spambots. You need JavaScript enabled to view it. 855-690-0340